Login to Your Account

Going Up Against Lucentis

Regeneron: VEGF Trap Gets Potential $320M Bayer Deal

By Randall Osborne

Friday, October 20, 2006
Bayer Healthcare is paying Regeneron Pharmaceuticals Inc. up to $320 million - including $75 million up front - in a deal centered on VEFG Trap for diseases of the eye, and expects to start a Phase III trial in the first half of next year comparing the drug to Lucentis against age-related macular degeneration. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription